China Health Group Inc (8225) Fair Value & Analysis
Healthcare · HK · Market cap HK$93.6M
Fair value as of: Aug 13, 2026
From 7 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$0.1114 to HK$0.1120 (+0.5%) since Aug 6, 2026. Share price −16.7% over the past month.
A solid business, screening 40% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$0.0880). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.0710 – HK$0.5200 · fair‑value band HK$0.0880 – HK$0.1360 · the HK$0.0800 price screens below the HK$0.1120 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
China Health Group Inc (8225) currently trades at HK$0.0800, while our model-based Fair Value estimate is HK$0.1120, implying the stock looks roughly 40.0% undervalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, China Health Group Inc generated revenue of HK$28.6M at a net margin of -52.4%. Revenue declined 14.9% year over year. It earns a return on equity of -24.0%. The balance sheet holds a net cash position of HK$23.4M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.0880 (bear case) to HK$0.1360 (bull case); at HK$0.0800, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 60% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at 40%, 8225 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: DCF Models (HK$0.1200) versus Asset-Based (HK$0.0400). Highest evidence: Growth DCF (80).
Notify me when 8225 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
China Health Group Inc., together with its subsidiaries, researches and develops bio, natural, and synthetic drugs in the People's Republic of China.
Full company description
China Health Group Inc., together with its subsidiaries, researches and develops bio, natural, and synthetic drugs in the People's Republic of China. It engages in the pharmacodynamics and clinical research of drugs; provision of post market and contracted pharmaceutical development services; and technological transfer and services for the research and development of drugs. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in February 2015. China Health Group Inc. was founded in 1998 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
China Health Group Inc reported revenue of HK$27.8M in FY2025 versus HK$83.6M in FY2021, a compound −24.0%/yr. Reported net income was −HK$14.6M in FY2025.
Watch 8225: get an alert when its fair value changes →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $243.84 | $132.17 | -46% |
| Illumina, Inc ILMN | $192.91 | $95.51 | -50% |
| Mettler-Toledo International Inc MTD | $1,437 | $615.78 | -57% |
Compare China Health Group Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is China Health Group Inc (8225) overvalued or undervalued?
What is the fair value of 8225?
What is the quality score of 8225?
What is the revenue of China Health Group Inc (8225)?
What is the net profit margin of 8225?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track China Health Group Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.